Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from prednisone to dexamethasone with continued abiraterone after PSA progression in hormone-sensitive metastatic prostate cancer
2021-000943-30Phase 2Terminated
- Sponsor
- SOGUG
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) comparing Abiraterone + prednisone continuation with Abiraterone + dexamethasone switch (2 arms). Primary endpoint: Rate or proportion of patients with progression by PSA at 12 weeks. Started Jul 2021; status: terminated.
02
Drugs
abirateroneprednisonedexamethasone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-000943-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000943-30.